2022
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma
Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.Peer-Reviewed Original ResearchMeSH KeywordsFlow CytometryHumansLymphoma, T-CellLymphoma, T-Cell, PeripheralPrognosisRetrospective StudiesConceptsPeripheral T-cell lymphomaT-cell lymphomaBone marrow involvementBlood involvementFlow cytometryMarrow involvementNodal subtypesAggressive peripheral T-cell lymphomaNodal T-cell lymphomasNegative flow cytometryPeripheral blood involvementPositive flow cytometryMalignant T cellsMalignant tumor cellsMedian PFSTime ofdiagnosisOverall survivalLymph nodesPoor outcomeDisease stagePeripheral bloodT cellsPrognostic measuresRare subgroupLymphoma
2021
How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCare
2019
A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma
Afifi S, Mohamed S, Zhao J, Foss F. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma. Expert Opinion On Drug Safety 2019, 18: 769-776. PMID: 31303060, DOI: 10.1080/14740338.2019.1643837.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaTreatment optionsTreatment of CTCLSkin-homing T cellsRare non-Hodgkin lymphomaSystemic treatment optionsMF/SSNew treatment optionsNon-Hodgkin lymphomaDrug Administration approvalDrug safety evaluationLow response rateAdvanced diseaseAdult patientsPrior linesAdministration approvalT cellsMogamulizumabResponse rateAgent efficacyPatientsRecent FoodLymphomaDisease states
2018
Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate
Foss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.Peer-Reviewed Original ResearchThe outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattone C, Moskowitz A, Spina M, Biasoli I, Manni M, Federico M. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica 2018, 103: 1191-1197. PMID: 29599200, PMCID: PMC6029527, DOI: 10.3324/haematol.2017.186577.Peer-Reviewed Original ResearchConceptsBone marrow transplantationInternational T-cell ProjectPeripheral T-cell lymphoma patientsT-cell lymphoma patientsT-cell ProjectOverall survivalMarrow transplantationLymphoma patientsRelapsed Peripheral T-Cell LymphomaPeripheral T-cell lymphomaUnivariate Cox regression analysisChemotherapy-sensitive diseaseMedian overall survivalFirst-line therapyFirst-line treatmentOverall survival rateSurvival of patientsCox regression analysisEnd of treatmentStandard of careT-cell lymphomaMedian followPrimary refractoryBetter OSRefractory/
2017
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 2017, 131: 888-898. PMID: 29233821, PMCID: PMC5824337, DOI: 10.1182/blood-2017-08-802470.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAged, 80 and overClass I Phosphatidylinositol 3-KinasesClass Ib Phosphatidylinositol 3-KinaseFemaleHumansIsoquinolinesLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralMaleMaximum Tolerated DoseMiddle AgedPhosphoinositide-3 Kinase InhibitorsPrognosisPurinesSafetySkin NeoplasmsTissue DistributionConceptsT-cell lymphomaPhospho-AktImmunosuppressive M2-like phenotypeCutaneous T-cell lymphomaNonmalignant immune cellsOpen-label studySerum cytokine profilesAcceptable safety profileImmune-mediated effectsPhase 1 trialOverall response rateM1-like phenotypePatient-derived xenograftsTumor-associated macrophagesM2-like phenotypeInflammatory M1-like phenotypeT cell growthRefractory PTCLTransaminase increaseAdverse eventsClinical responseCytokine profileMaculopapular rashComplete responsePreclinical evidenceDuvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood 2017, 131: 877-887. PMID: 29191916, PMCID: PMC6033052, DOI: 10.1182/blood-2017-05-786566.Peer-Reviewed Original ResearchConceptsT-cell lymphomaChronic lymphocytic leukemiaIndolent non-Hodgkin lymphomaOral dual inhibitorAdvanced hematologic malignanciesComplete responseTransaminase increaseHematologic malignanciesRefractory chronic lymphocytic leukemiaPeripheral T-cell lymphomaCutaneous T-cell lymphomaAlanine transaminase increaseHematologic malignancy treatmentDose-escalation phaseSevere adverse eventsPhase 1 studyDual inhibitorOverall response rateLate-stage clinical developmentNon-Hodgkin lymphomaCLL tumor cellsRange of dosesAdverse eventsClinical responseMedian time
2016
Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction
Gibson JF, Huang J, Liu KJ, Carlson KR, Foss F, Choi J, Edelson R, Hussong JW, Mohl R, Hill S, Girardi M. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. Journal Of The American Academy Of Dermatology 2016, 74: 870-877. PMID: 26874819, PMCID: PMC4835257, DOI: 10.1016/j.jaad.2015.12.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCross-Sectional StudiesFemaleFlow CytometryHematologic TestsHumansInternationalityLymphoma, T-Cell, CutaneousMaleMiddle AgedMycosis FungoidesNeoplasm InvasivenessNeoplasm StagingPolymerase Chain ReactionPractice Guidelines as TopicPredictive Value of TestsPrognosisRare DiseasesReceptors, Antigen, T-CellRetrospective StudiesSezary SyndromeSkin NeoplasmsSocieties, MedicalConceptsCutaneous T-cell lymphomaT-cell lymphomaCurrent clinical practiceClinical practicePredictive valueNegative predictive valuePositive predictive valueCurrent International SocietyT cell receptorImmunophenotypic abnormalitiesEvidence of clonalitySingle centerTumor burdenBlood assessmentClinical benefitPeripheral bloodCohort casesDisease burdenPolymerase chain reactionStaging criteriaChain restrictionRetrospective analysisMalignant cellsFlow cytometryDiagnostic algorithm
2015
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal Of Clinical Oncology 2015, 33: 3766-3773. PMID: 26438120, PMCID: PMC4979132, DOI: 10.1200/jco.2015.61.7142.Peer-Reviewed Original ResearchConceptsMF/Sézary syndromeAdvanced-stage MF/Sézary syndromeMedian overall survivalSézary syndromeIndependent prognostic markerOverall survivalPrognostic markerWorse survivalMycosis fungoidesAdvanced MF/SSSurvival rateAdvanced-stage mycosis fungoidesIdentical T-cell clonesStage IIB diseaseStage III diseaseStage IV diseaseSingle-center trialAdvanced-stage patientsIndependent prognostic valueSerum lactate dehydrogenasePrognostic index modelSpecific prognostic markersLarge cell transformationT cell clonesIIB diseaseRomidepsin for the Treatment of Peripheral T‐Cell Lymphoma
Iyer SP, Foss FF. Romidepsin for the Treatment of Peripheral T‐Cell Lymphoma. The Oncologist 2015, 20: 1084-1091. PMID: 26099743, PMCID: PMC4571813, DOI: 10.1634/theoncologist.2015-0043.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaT-cell lymphomaHistone deacetylase inhibitorsPrior therapySpecialty centersTherapeutic approachesExpert hematopathologistsTreatment of PTCLDeacetylase inhibitorsPivotal phase II studiesCutaneous T-cell lymphomaPrior systemic therapyCommon adverse eventsObjective response ratePhase II studyFirst-line treatmentTreatment of patientsNon-Hodgkin lymphomaDifficulty of diagnosisAsthenic conditionsHeavy pretreatmentInduction chemotherapyAdvanced diseaseAdverse eventsUtility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Annals Of Oncology 2015, 26: 774-779. PMID: 25605745, PMCID: PMC4374388, DOI: 10.1093/annonc/mdv010.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaInternational Workshop CriteriaFDG-PET scansRefractory peripheral T-cell lymphomaBaseline FDG-PET scanCR/CRuT-cell lymphomaPositron emission tomographyConventional radiologyPET criteriaStable diseaseEnd pointFDG-PETConventional stagingPET statusResponse assessmentPivotal phase 2 trialEmission tomographyDeoxyglucose positron emission tomographyExploratory end pointsObjective response ratePET-positive diseasePrimary end pointProgression-free survivalPhase 2 studyPhase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 2015, 125: 1883-1889. PMID: 25605368, PMCID: PMC4375715, DOI: 10.1182/blood-2014-09-600924.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaEfficacy of mogamulizumabT-cell lymphomaAnti-CC chemokine receptor 4 monoclonal antibodyFrequent treatment-emergent adverse eventsCutaneous T-cell lymphoma patientsTreatment-emergent adverse eventsT-cell lymphoma patientsSignificant hematologic effectsInfusion-related reactionsPhase 1/2 studyOverall response ratePhase 3 investigationAnti-CCR4 antibodyEvaluable patientsBlood involvementAdverse eventsGrade 1/2Sézary syndromeComplete responseMycosis fungoidesLymphoma patientsHematologic effectsDisease progressionMogamulizumab
2014
CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature
James E, Sokhn JG, Gibson JF, Carlson K, Subtil A, Girardi M, Wilson LD, Foss F. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leukemia & Lymphoma 2014, 56: 951-957. PMID: 24996443, DOI: 10.3109/10428194.2014.938331.Peer-Reviewed Original ResearchConceptsT-cell lymphomaSmall/medium-sized pleomorphic T-cell lymphomaPleomorphic T-cell lymphomaPCSM-TCLSystemic involvementCase seriesWorld Health Organization-European OrganizationIndolent T-cell lymphomaRare T-cell lymphomaLocalized radiationRetrospective case seriesCD7 lossReview of literatureComplete remissionCytotoxic chemotherapyMedian ageFavorable prognosisRetrospective studyTreatment of cancerExcisional biopsyCD4Local modalitiesPatientsLymphomaInvasive features
2013
Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides
Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. Journal Of The American Academy Of Dermatology 2013, 69: 537-543. PMID: 23849563, DOI: 10.1016/j.jaad.2013.04.063.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAge FactorsAgedAnalysis of VarianceCohort StudiesDermatomycosesDose Fractionation, RadiationDose-Response Relationship, RadiationElectronsFemaleHumansIncidenceMaleMiddle AgedMultivariate AnalysisMycosis FungoidesNeoplasm InvasivenessNeoplasm StagingPrognosisRadiodermatitisRadiotherapy DosageRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex FactorsSkin Diseases, BacterialSkin NeoplasmsWhole-Body IrradiationConceptsTotal skin electron beam therapyMycosis fungoidesSkin infectionsElectron beam therapyAcute toxicityBeam therapyAcute treatment toxicityRetrospective study designIncidence of infectionRisk of infectionCommon toxicitiesTreatment toxicityCutaneous infectionsSkin painBaseline incidenceToxicity gradeGrade 3Modern seriesGrade 2Grade 1Consecutive coursesFungoidesInfectionStudy designGrade 4
2012
Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study
Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study. Clinical Lymphoma Myeloma & Leukemia 2012, 12: 238-243. PMID: 22542448, DOI: 10.1016/j.clml.2012.01.010.Peer-Reviewed Original ResearchConceptsMedian progression-free survivalToxicity-related discontinuationProgression-free survivalIndependent central reviewMedian survivalInvestigator assessmentMycosis fungoidesCentral reviewMedian durationAggressive diseaseRetrospective analysisGrade 4 adverse eventsPrior systemic therapySubgroup efficacy analysesObjective response rateTransformed Mycosis FungoidesPROPEL StudyAdverse eventsObjective responseSystemic therapyCutaneous lesionsEfficacy analysisPoor prognosisTreatment optionsMedian number
2011
Polymorphisms in immune function genes and non-Hodgkin lymphoma survival
Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship 2011, 6: 102-114. PMID: 22113576, PMCID: PMC3326600, DOI: 10.1007/s11764-010-0164-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCase-Control StudiesConnecticutCytokinesDisease-Free SurvivalFemaleGene FrequencyGenotypeHumansKaplan-Meier EstimateLymphoma, Non-HodgkinMiddle AgedModels, GeneticPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSocioeconomic FactorsSurvival AnalysisSurvivorsYoung AdultConceptsNon-Hodgkin lymphomaNHL survivalHazard ratioCytokine genesNon-Hodgkin lymphoma survivalCox proportional hazards modelIncident NHL casesConnecticut Tumor RegistryDisease-free survivalKaplan-Meier curvesRisk of deathProportional hazards modelCombination of polymorphismsImmune function genesIL6 genotypeNHL prognosisTumor RegistryHistologic typeTumor characteristicsDecreased riskSecondary cancersNHL casesTumor interactionCancer occurrenceLymphoma survivalMolecular Predictors of Response in Aggressive T-cell Lymphomas
Foss FM. Molecular Predictors of Response in Aggressive T-cell Lymphomas. The Cancer Journal 2011, 17: 142-148. PMID: 21427558, DOI: 10.1097/ppo.0b013e31821828b7.Peer-Reviewed Original ResearchConceptsAggressive T-cell lymphomaT-cell lymphomaNatural killer cellsNon-Hodgkin lymphomaWorld Health OrganizationKiller cellsInferior outcomesPrognostic characterizationMore accurate diagnosisTreatment strategiesMolecular predictorsTherapeutic strategiesAccurate diagnosisDistinct entityLymphomaGene expression profilingHealth OrganizationHeterogeneous groupRecent dataMolecular featuresDevelopment of novelExpression profilingMolecular analysisRegimensMalignancy
2010
Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
Armitage JO, Hsi ED, Foss FM. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clinical Advances In Hematology And Oncology 2010, 8: 1-15. PMID: 21491667.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaPTCL subtypesTherapeutic regimensDisease state awarenessAggressive disease courseT-cell markersB-cell lymphomaMost patientsRefractory diseaseDisease courseIndolent courseAggressive diseaseLymphoproliferative disordersPoor prognosisTherapeutic overviewEffective treatmentProper diagnosisLymphomaRegimensSubtypesHeterogeneous groupPatientsPrognosisDisease
2009
Alcohol consumption and non-Hodgkin lymphoma survival
Han X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, Leaderer B, Zhao P, Dai M, Zhang Y. Alcohol consumption and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship 2009, 4: 101-109. PMID: 20039144, PMCID: PMC3141078, DOI: 10.1007/s11764-009-0111-4.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaNon-Hodgkin lymphomaAlcohol consumptionHazard ratioNHL subtypesNHL survivalNon-Hodgkin lymphoma survivalCox proportional hazards modelLarge B-cell lymphomaDisease-free survivalBetter overall survivalKaplan-Meier methodModerate alcohol drinkersProportional hazards modelB-cell lymphomaLower death ratesIntroductionEpidemiological studiesFree survivalOverall survivalNHL patientsAlcohol drinkersIncident casesMethodsA cohortAlcohol drinkingDLBCL patients
2008
Cutaneous T-cell Lymphoma
Lansigan F, Choi J, Foss FM. Cutaneous T-cell Lymphoma. Hematology/Oncology Clinics Of North America 2008, 22: 979-996. PMID: 18954747, DOI: 10.1016/j.hoc.2008.07.014.Peer-Reviewed Original Research